Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
19.12.24 | Novo completes $16.5bn takeover of Catalent | ||
19.12.24 | Ottimo raises $140m for its PD-1/VEGF cancer drug | ||
19.12.24 | MSD makes its obesity move with $2bn Hansoh deal | ||
19.12.24 | Mesoblast finally pushes GvHD cell therapy over finish line | ||
18.12.24 | Novo Holdings leads $100m round for novel painkiller biotech | ||
18.12.24 | Sensorion encouraged by deafness gene therapy data | ||
18.12.24 | Lilly's Alzheimer's drug Kisunla is cleared in China | ||
18.12.24 | MSD eyes June verdict for paediatric RSV antibody | ||
18.12.24 | UnitedHealth killing suspect gets first-degree murder charge | ||
17.12.24 | Teva, Sanofi score well with anti-TL1A drug in IBD test | ||
17.12.24 | Study backs Closed Loop's drug+digital blood pressure plan | ||
17.12.24 | End of the line for MSD's TIGIT, LAG-3 cancer drugs | ||
17.12.24 | FDA dents J&J's blockbuster hopes for Rybrevant | ||
17.12.24 | PBM reform looms in end-of-year US legislation package | ||
16.12.24 | FDA clears Neurocrine drug for rare adrenal disorder | ||
16.12.24 | Novo sets aside $1.2bn for rare diseases plant | ||
16.12.24 | Galderma adds new indication for blockbuster hope Nemluvio | ||
16.12.24 | New drugs 'benefit patients, but maybe not populations' | ||
16.12.24 | AbbVie adds psoriasis med with Nimble takeover | ||
13.12.24 | ICER identifies new crop of 'unsupported' drug price rises | ||
13.12.24 | Top podcaster spread health misinformation, claims BBC probe | ||
13.12.24 | Editas axes two-thirds of its staff, including its CMO | ||
13.12.24 | Safety fear halts Keros PAH trial dosing, hitting its shares | ||
13.12.24 | Carlyle backs Essential refinancing and other funding news | ||
12.12.24 | NIH abandons trial of SIGA's mpox drug |